Trial · NCT02673333
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 20
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Increased AST/ALT | Investigations | Pembrolizumab | 9 | 39 | |
| other | Hypocalcemia | Metabolism and nutrition disorders | Pembrolizumab | 4 | 39 | |
| other | Increased Alkaline Phosphatase | Investigations | Pembrolizumab | 4 | 39 | |
| other | Lymphopenia | Investigations | Pembrolizumab | 2 | 39 | |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Pembrolizumab | 2 | 39 | |
| other | Increased Creatinine | Investigations | Pembrolizumab | 2 | 39 | |
| other | Fatigue | General disorders | Pembrolizumab | 8 | 39 | |
| other | Chills | General disorders | Pembrolizumab | 2 | 39 | |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab | 3 | 39 | |
| other | Nausea | Gastrointestinal disorders | Pembrolizumab | 2 | 39 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Pembrolizumab | 7 | 39 | |
| other | Rash | Skin and subcutaneous tissue disorders | Pembrolizumab | 3 | 39 | |
| other | Hyperpigmentation | Skin and subcutaneous tissue disorders | Pembrolizumab | 2 | 39 | |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Pembrolizumab | 2 | 39 | |
| serious | Increased AST/ALT | Investigations | Pembrolizumab | 4 | 39 | |
| serious | Hypocalcemia | Metabolism and nutrition disorders | Pembrolizumab | 1 | 39 | |
| serious | Hypoalbuminemia | Metabolism and nutrition disorders | Pembrolizumab | 1 | 39 | |
| serious | Hypokalemia | Metabolism and nutrition disorders | Pembrolizumab | 1 | 39 | |
| serious | Hypophosphatemia | Metabolism and nutrition disorders | Pembrolizumab | 1 | 39 | |
| serious | Hypomagnesemia | Metabolism and nutrition disorders | Pembrolizumab | 1 | 39 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02673333/events